Literature DB >> 34055209

Modulating Androgen Receptor in the Therapeutic Intervention for Prostate Cancer and Kennedy's Disease.

Robert B Kargbo1.   

Abstract

Entities:  

Year:  2021        PMID： 34055209      PMCID： PMC8155263          DOI： 10.1021/acsmedchemlett.1c00177

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.345


× No keyword cloud information.
  6 in total

Review 1.  Advances in Discovering Deubiquitinating Enzyme (DUB) Inhibitors.

Authors:  Nathan J Schauer; Robert S Magin; Xiaoxi Liu; Laura M Doherty; Sara J Buhrlage
Journal:  J Med Chem       Date:  2019-11-20       Impact factor: 7.446

Review 2.  Advances in the computational development of androgen receptor antagonists.

Authors:  Xueping Hu; Xin Chai; Xuwen Wang; Mojie Duan; Jinping Pang; Weitao Fu; Dan Li; Tingjun Hou
Journal:  Drug Discov Today       Date:  2020-05-18       Impact factor: 7.851

Review 3.  Interactions between androgen receptor signaling and other molecular pathways in prostate cancer progression: Current and future clinical implications.

Authors:  Chiara Pisano; Marcello Tucci; Rosario Francesco Di Stefano; Fabio Turco; Giorgio Vittorio Scagliotti; Massimo Di Maio; Consuelo Buttigliero
Journal:  Crit Rev Oncol Hematol       Date:  2020-11-27       Impact factor: 6.312

Review 4.  Androgen receptor in breast cancer: A wolf in sheep's clothing? A lesson from prostate cancer.

Authors:  Samanta Salvi; Massimiliano Bonafè; Sara Bravaccini
Journal:  Semin Cancer Biol       Date:  2019-04-16       Impact factor: 15.707

5.  A critical update on the strategies towards modulators targeting androgen receptors.

Authors:  Hongyu Luan; Pengfei Xu; Ying Meng; Zhiyu Li; Jinlei Bian
Journal:  Bioorg Med Chem       Date:  2020-05-12       Impact factor: 3.641

Review 6.  A novel GPCR target in correlation with androgen deprivation therapy for prostate cancer drug discovery.

Authors:  Jing-Yan Tian; Chang-Liang Chi; Ge Bian; Feng-Jun Guo; Xiao-Qing Wang; Bing Yu
Journal:  Basic Clin Pharmacol Toxicol       Date:  2020-12-01       Impact factor: 4.080
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.